Omeros Shares Surge as YARTEMLEA Sales Crush Expectations in Q2
First full quarter of YARTEMLEA delivers $28.5M net product sales and turns Omeros profitable on an adjusted basis in Q2 2026.
/ 5 items
#OMER↓
H.C. Wainwright Reiterates Buy on Omeros After AstraZeneca’s Ultomiris Phase 3 Miss
AstraZeneca’s Ultomiris Phase 3 miss in adult HSCT-TMA is a clear positive for Omeros’ Yartemlea, removing a key rival.
Omeros Shares Plunge After CHMP Rejects Narsoplimab for TA-TMA
Omeros shares fell sharply after the CHMP gave a negative opinion on its drug narsoplimab for transplant-associated thrombotic microangiopathy. Company plans re-examination.
FDA Approves First-Ever Treatment for Deadly Stem Cell Transplant Complication
Omeros' (OMER) Yartemlea becomes the first FDA-approved drug for TA-TMA, a life-threatening complication affecting stem cell transplant patients, with launch planned for January 2026.
Omeros Strikes $2.1 Billion Deal, Granting Novo Nordisk Exclusive Global Rights to Zaltenibart
Novo Nordisk acquired the rare disease drug zaltenibart from Omeros for up to $2.1B. It treats disorders like PNH & Novo plans Phase 3.